Press release from Companies
Publicerat: 2025-06-19 10:36:14
VibroSense Dynamics AB (publ) announces today that the company has received the official certificate from the Chinese pharmaceutical authority NMPA (National Medical Products Administration). The company had previously informed the market that the NMPA approval had been granted, and with the formal certificate in hand, the three-year commercial agreement with the exclusive Chinese partner UMCare now comes into effect.
The agreement, which has a total value of approximately EUR 3.74 million, covers the launch, marketing and sales of VibroSense products in the Chinese market.
The certificate applies to the VibroSense Meter® II, a medical device system used to measure vibration thresholds in the foot as a diagnostic aid in assessing peripheral nerve damage, for example in people with diabetes – a patient group that is rapidly increasing in China.
For more information, please contact:
Tarik Cengiz, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.com
“The new Gold Standard for reliable
detection of nerve damage”
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.
Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.
